CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment - PubMed
3 hours ago
- #obesity
- #CagriSema
- #meta-analysis
- CagriSema, a dual therapy combining semaglutide with cagrilintide, was compared to semaglutide monotherapy or placebo in obesity treatment.
- A systematic review and meta-analysis included 4 randomized controlled trials (RCTs) with 4,419 participants (3,055 on CagriSema, 1,364 controls).
- CagriSema significantly reduced percent weight loss (Cohen's d: -1.38; 95% CI: -1.84 to -0.91) and showed greater absolute weight loss (-11 kg), waist circumference reduction (-9.41 cm), and systolic blood pressure decrease (-7.06 mmHg).
- Gastrointestinal adverse events were more frequent with CagriSema (RR: 1.32).
- CagriSema achieved superior weight reduction compared to semaglutide or placebo but requires careful tolerability monitoring and longer-term data.